Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study.
作者信息
Kishi Taro, Iwama Yasuhiro, Sasagawa Yuji, Hiraoka Shuichi, Kamei Aya, Iwata Nakao
机构信息
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.
Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
出版信息
Psychiatry Clin Neurosci. 2023 Jun;77(6):365-366. doi: 10.1111/pcn.13540. Epub 2023 Mar 17.
Abstract
摘要
相似文献
1
Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study.
Psychiatry Clin Neurosci. 2023 Jun;77(6):365-366. doi: 10.1111/pcn.13540. Epub 2023 Mar 17.
2
Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
Neuropsychopharmacol Rep. 2020 Jun;40(2):138-149. doi: 10.1002/npr2.12103. Epub 2020 Mar 16.
3
Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study.
J Clin Psychiatry. 2020 Dec 15;82(1):20m13602. doi: 10.4088/JCP.20m13602.
4
Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.
Psychopharmacology (Berl). 2016 Jul;233(14):2663-74. doi: 10.1007/s00213-016-4295-9. Epub 2016 Jun 8.
5
Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data.
Neuropsychopharmacol Rep. 2024 Mar;44(1):234-239. doi: 10.1002/npr2.12389. Epub 2023 Nov 5.
6
Asenapine versus placebo for schizophrenia.
Cochrane Database Syst Rev. 2015 Nov 24;2015(11):CD011458. doi: 10.1002/14651858.CD011458.pub2.
7
Proceedings: Butaclamol in the treatment of schizophrenia--a comparison of two treatment methods.
Psychopharmacol Bull. 1976 Jan;12(1):31-4.
8
Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
J Child Adolesc Psychopharmacol. 2015 Jun;25(5):384-96. doi: 10.1089/cap.2015.0027.
9
Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
Int J Clin Pract. 2009 Dec;63(12):1762-84. doi: 10.1111/j.1742-1241.2009.02228.x. Epub 2009 Oct 14.
10
Continuation rate for asenapine and brexpiprazole treatment in elderly patients with schizophrenia.
Psychogeriatrics. 2021 Nov;21(6):950-951. doi: 10.1111/psyg.12760. Epub 2021 Sep 5.
引用本文的文献
1
Research progress in estrogen as an adjunctive therapy for schizophrenia.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Nov 28;49(11):1849-1860. doi: 10.11817/j.issn.1672-7347.2024.240289.
2
Effect of single-administration of D-sorbitol pretreatment on the bitterness and continued willingness to take asenapine: a randomized, single-blind, placebo-controlled, crossover trial.
BMC Psychiatry. 2024 Jan 30;24(1):81. doi: 10.1186/s12888-024-05549-x.
本文引用的文献
1
Long-term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow-up for 52 weeks (P06125)-Secondary publication.
Neuropsychopharmacol Rep. 2023 Sep;43(3):328-337. doi: 10.1002/npr2.12342. Epub 2023 May 25.
2
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Mol Psychiatry. 2022 Feb;27(2):1136-1144. doi: 10.1038/s41380-021-01334-4. Epub 2021 Oct 12.
3
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11.
4
Safety and tolerability of antipsychotic polypharmacy.
Expert Opin Drug Saf. 2012 Jul;11(4):527-42. doi: 10.1517/14740338.2012.683523. Epub 2012 May 8.
5
The positive and negative syndrome scale (PANSS) for schizophrenia.
Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
Zotero 插件